Gunzler SA - Search Results

1

Effect of low concentrations of apomorphine on parkinsonism in a randomized, placebo-controlled, crossover study.

Gunzler SA, Koudelka C, Carlson NE, Pavel M, Nutt JG. Gunzler SA, et al. Arch Neurol. 2008 Feb;65(2):193-8. doi: 10.1001/archneurol.2007.58. Arch Neurol. 2008. PMID: 18268187 Free PMC article. Clinical Trial.

2

Severity dependent distribution of impairments in PSP and CBS: Interactive visualizations.

Brittain C, McCarthy A, Irizarry MC, McDermott D, Biglan K, Höglinger GU, Lorenzl S, Del Ser T, Boxer AL; AL-108-231 Study Group; PROPSPERA investigators; 4RNTI-1authors; Tau Restoration on PSP (TAUROS) Investigators. Brittain C, et al. Parkinsonism Relat Disord. 2019 Mar;60:138-145. doi: 10.1016/j.parkreldis.2018.08.025. Epub 2018 Sep 4. Parkinsonism Relat Disord. 2019. PMID: 30201421 Free PMC article. Clinical Trial.

3

Joubert syndrome surviving to adulthood associated with a progressive movement disorder.

Gunzler SA, Stoessl AJ, Egan RA, Weleber RG, Wang P, Nutt JG. Gunzler SA, et al. Mov Disord. 2007 Jan 15;22(2):262-5. doi: 10.1002/mds.21263. Mov Disord. 2007. PMID: 17149728

4

Low doses of apomorphine transiently reduce locomotor activity in MPTP-treated mice.

Gunzler SA, Shakil S, Carlson NE, Nutt JG, Meshul CK. Gunzler SA, et al. Neurosci Lett. 2007 Nov 27;428(2-3):64-7. doi: 10.1016/j.neulet.2007.09.049. Epub 2007 Oct 2. Neurosci Lett. 2007. PMID: 17964074

5

Effects of a NR2B selective NMDA glutamate antagonist, CP-101,606, on dyskinesia and Parkinsonism.

Nutt JG, Gunzler SA, Kirchhoff T, Hogarth P, Weaver JL, Krams M, Jamerson B, Menniti FS, Landen JW. Nutt JG, et al. Among authors: gunzler sa. Mov Disord. 2008 Oct 15;23(13):1860-6. doi: 10.1002/mds.22169. Mov Disord. 2008. PMID: 18759356 Free PMC article. Clinical Trial.

6

Foot-tapping rate as an objective outcome measure for Parkinson disease clinical trials.

Gunzler SA, Pavel M, Koudelka C, Carlson NE, Nutt JG. Gunzler SA, et al. Clin Neuropharmacol. 2009 Mar-Apr;32(2):97-102. doi: 10.1097/WNF.0B013E3181684C22. Clin Neuropharmacol. 2009. PMID: 18978495 Clinical Trial.

7

Apomorphine in the treatment of Parkinson disease and other movement disorders.

Gunzler SA. Gunzler SA. Expert Opin Pharmacother. 2009 Apr;10(6):1027-38. doi: 10.1517/14656560902828344. Expert Opin Pharmacother. 2009. PMID: 19364250 Review.

8

Systematic review of the pharmacoeconomics of Parkinson disease medications.

Wang AS, Gunzler SA. Wang AS, et al. Among authors: gunzler sa. Expert Opin Pharmacother. 2019 Sep;20(13):1659-1670. doi: 10.1080/14656566.2019.1622091. Epub 2019 May 31. Expert Opin Pharmacother. 2019. PMID: 31150294

9

NMDAR antibody encephalitis overlapping with CLIPPERS syndrome in a psoriasis patient on adalimumab.

Martin T, Duke S, Kumar V, Fadhil A, Ibrahim R, Palmer K, Yazdani S, Devereaux M, Gunzler S, Serra A, Abboud H. Martin T, et al. J Neurol. 2021 Feb;268(2):714-716. doi: 10.1007/s00415-020-10341-4. Epub 2021 Jan 2. J Neurol. 2021. PMID: 33388924 No abstract available.

10

Quality Improvement in Neurology: 2020 Parkinson Disease Quality Measurement Set Update.

Chou KL, Martello J, Atem J, Elrod M, Foster ER, Freshwater K, Gunzler SA, Kim H, Mahajan A, Sarva H, Stebbins GT, Lee E, Yang L. Chou KL, et al. Among authors: gunzler sa. Neurology. 2021 Aug 3;97(5):239-245. doi: 10.1212/WNL.0000000000012198. Neurology. 2021. PMID: 34341076 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

41 results

Search Page

Filters